GLP-1 weight loss drugs could transform public health, but access to medication alone will not deliver their full potential. Reset Health CEO Oliver McGuinness argues that the NHS needs sustainable investment and clinically supported pathways that improve patient outcomes, retention and long-term value GLP-1 medications – weight loss drugs such as Mounjaro and Wegovy…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2026 All rights reserved LaingBuisson
